Join WhatsApp

Folow Facebook

Subscribe YouTube

Follow Instagram

Hyderabad: Biological E. Limited (BE), the Hyderabad-based vaccines and pharmaceuticals major, has announced that its 14-valent Pneumococcal Conjugate Vaccine (PCV), PNEUBEVAX 14® , has been granted pre-qualification (PQ) status by the World Health Organization (WHO). The approval marks BE’s 11th WHO-prequalified vaccine .

PNEUBEVAX 14® protects against 14 Streptococcus pneumoniae serotypes , including 22F and 33F — strains not covered by select other paediatric PCVs currently available in India. Designed for administration in infants from six weeks of age, the vaccine aims to prevent serious conditions such as pneumonia, meningitis and sepsis as part of routine immunisation schedules.

According to BE, clini

See Full Page